Oppenheimer Reiterates Outperform on Perspective Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has reiterated an Outperform rating for Perspective Therapeutics (AMEX:CATX) and maintained a price target of $22.
October 11, 2024 | 5:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jeff Jones has reiterated an Outperform rating for Perspective Therapeutics and maintained a $22 price target, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $22 price target by a reputable analyst suggests positive sentiment and potential upside for CATX, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100